Pulmonx (LUNG) to Release Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is set to issue its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulmonx Stock Down 1.0 %

LUNG opened at $6.03 on Monday. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. The firm has a market cap of $234.06 million, a P/E ratio of -3.92 and a beta of 0.64. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The business’s fifty day simple moving average is $7.30 and its 200 day simple moving average is $7.29.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Wells Fargo & Company reduced their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Canaccord Genuity Group increased their target price on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Insider Buying and Selling

In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the transaction, the director now directly owns 1,111,974 shares in the company, valued at $8,995,869.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the transaction, the director now directly owns 1,111,974 shares in the company, valued at $8,995,869.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven S. Williamson acquired 14,245 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the acquisition, the chief executive officer now owns 219,531 shares in the company, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 50,351 shares of company stock worth $361,494. 5.70% of the stock is owned by company insiders.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.